Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.
Grindr Users Take PrEP More and Have Lower HIV Rates, but Have Higher Rate of STIs Than Men Not on the App
Gay and bisexual men who used Grindr were having more sex acts associated with increased risk, but were more likely to use PrEP or be open to it, which translated to lower HIV incidence.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
Several PrEP studies presented at IDWeek focused on the need for better education among clinicians and medical students regarding not only how PrEP works and whom it can benefit but also that it even exists as an HIV prevention option.
At the recent IDWeek 2016 conference in New Orleans, researchers presented data to try and answer the question: What's causing the rising STI rates among gay and bisexual men over the past several years?
As we inch closer to an HIV cure, the next big step is making long-acting antiretroviral therapy the norm and saying goodbye to one pill once a day. Such drugs could be used for both treatment and prevention. Here’s a review of the research so far.
Leading HIV clinician-researcher Carlos Del Rio, M.D., recently gave a whirlwind tour of 18 major studies that are among the most groundbreaking new scientific findings in HIV over the past 12 months.
HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.